Kura Oncology

Starting in 2010, LLS TAP supported a promising University of Michigan research project led by Jolanta Grembecka, PhD, to develop new treatments for patients with a rare and lethal subtype of leukemia. Through TAP, LLS engaged chemists to improve the properties that produced lead compounds that exhibited potent anti-leukemic activity. In 2014, LLS introduced Kura Oncology to the project that ultimately led to Kura Oncology completing a licensing agreement with the University of Michigan to continue to develop these molecules.

Today, Kura Oncology remains committed to developing precision medicines for cancer, and LLS TAP prior investment into this project at the University of Michigan is now supporting a "Phase 2 registration-directed clinical trial in patients with NPM1-mutant relapsed or refractory AML."

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Ziftomenib (KO-539) is a selective and potent small molecule inhibitor of menin. The Phase 2 registration-directed clinical trial in patients with NPM1-mutant relapsed or refractory AML (NCT04067336) completed enrollment in May 2024, with topline data expected in early 2025.

In addition to continued evaluation of ziftomenib as a monotherapy in NPM1-mutant AML, Kura has initiated the KOMET-007 and KOMET-008 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML.

Recent News

• May 14, 2024 - announced completion of the Phase 2 portion of KOMET-001, a registration-directed clinical trial of ziftomenib (KO-539), in patients with relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). The Company expects to report topline data from the trial in early 2025
• April 22, 2024 - announced that ziftomenib has been granted Breakthrough Therapy Designation (BTD) by the FDA for the treatment of patients with relapsed/refractory (R/R) NPM1-mutant AML
• February 26, 2024 - announced that the first patient has been dosed in KOMET-008, a Phase 1 trial of ziftomenib, in combination with gilteritinib, FLAG-IDA or LDAC for the treatment of NPM1-mutant or KMT2A-rearranged acute myeloid leukemia (AML)
• January 30, 2024 - reported preliminary clinical data from the first 20 patients in KOMET-007 
• February 9, 2023 - announced that the first patients have been dosed in its KOMET-001 Phase 2 registration-directed trial of ziftomenib, the Company’s novel menin inhibitor, in patients with NPM1-mutant relapsed or refractory acute myeloid leukemia (AML)
• December 10, 2022 - announced updated clinical data from KOMET-001, a Phase 1/2 trial of the Company’s potent and selective menin inhibitor, ziftomenib, including an encouraging safety and tolerability profile and clinical activity in patients with relapsed/refractory acute myeloid leukemia (AML)
• December 13, 2021 - announced the presentation of new preclinical data for KO-539, the Company’s oral, potent and selective menin inhibitor, and its potential for synergistic activity in combination with venetoclax, a current standard of care in the treatment of patients with acute myeloid leukemia (AML), during a poster session today at the American Society of Hematology (ASH) Annual meeting in Atlanta
• June 24, 2021 - announced that the first patient has been dosed in the Phase 1b expansion cohort portion of KOMET-001, a Phase 1/2 clinical trial of the Company’s oral, potent and selective menin inhibitor, KO-539, in patients with relapsed or refractory acute myeloid leukemia (AML)

TAP Testimonial: Dr. Jolanta Grembecka, Associate Professor at The University of Michigan explains the role of LLS TAP in the early development of the KO-539 menin inhibitor.